Introduction
Mental health conditions such as schizophrenia and bipolar disorder can significantly affect emotional well-being, relationships, daily functioning, and overall quality of life. Many patients require ongoing treatment and long-term psychiatric care to help manage symptoms, maintain stability, and support daily functioning.
Caplyta is an atypical antipsychotic medication used to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder in adults. The medication works by affecting several neurotransmitter systems in the brain involved in mood, thinking, and behavior.
Caplyta is approved for use as both a standalone treatment and in combination with lithium or valproate for bipolar depression. The medication has a distinct receptor activity profile compared with some other atypical antipsychotic medications and was developed to help address symptoms associated with serious mental health conditions.
By affecting dopamine, serotonin, and glutamate-related pathways, Caplyta may help improve symptoms such as hallucinations, delusions, mood instability, depression, and other mood-related symptoms in some patients.
The medication is administered orally once daily and is typically taken with food. Ongoing psychiatric monitoring is important during treatment to help assess symptom control, medication tolerability, mood changes, and possible side effects.
Although psychiatric medications may provide important symptom management benefits, specialty mental health medications can also create affordability concerns. Patients may face high prescription costs, insurance prior authorization requirements, pharmacy pricing differences, and ongoing treatment expenses.
Prescription Hope works with patients who are searching for ways to make medications more affordable. Through patient assistance programs and medication advocacy support, Prescription Hope may help eligible individuals navigate the enrollment process for medications like Caplyta.
Understanding how Caplyta works, possible treatment benefits, side effects, and available medication access resources can help patients feel more informed when discussing treatment options with their healthcare provider.
What Is the Caplyta Patient Assistance Program?
The Caplyta Patient Assistance Program offers qualified patients access to affordable Caplyta.
Pharmaceutical manufacturers launch patient assistance programs to help qualified individuals access medications at affordable rates when they otherwise may not be able to afford the out-of-pocket costs of the medication.
Unfortunately, some of these programs have been known to be complicated and overwhelming to apply for.
Prescription Hope offers a solution to that problem.
How Expert Advocates Help Make Caplyta More Affordable
Professional Application Management
Prescription Hope serves qualified patients who struggle to afford their expensive brand-name medications.
We advocate for patients throughout the patient assistance program by applying on their behalf, collecting all necessary forms, documents, and signatures, and coordinating with the manufacturer.
Ongoing Advocacy and Refill Support
After a patient receives program approval, Prescription Hope continues to manage administrative tasks such as refill scheduling, document updates, program monitoring, and yearly renewals.
Caplyta Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Predictable Monthly Pricing
All of Prescription Hopes‘ services are covered by a predictable and simple $70.00 per month, per medication. We do not include hidden fees or upcharges, and no medication costs are added.
If a patient does not qualify, we work to help them find an alternative solution. We seek out substitute medications and their programs, discount cards, coupons, or other financial assistance.
And if we cannot find a way for you to save on your monthly medication costs, then you do not pay.
Caplyta Patient Assistance Eligibility
Those wondering about Caplyta eligibility should enroll with Prescription Hope to best determine whether they qualify.
All patient assistance programs maintain strict standards for eligibility. Some of the categories used to determine qualification include:
U.S. residency: All patients must be legal U.S. residents to qualify.
Prescription: All patients must have a valid prescription for their intended medication to qualify.
Insurance coverage: Each program’s insurance coverage requirements differ.
Income level: Income threshold criteria differ from program to program.
Simple Enrollment With Expert Support
Starting Your Journey
When a patient seeks to enroll in Caplyta assistance, they can do so by submitting the Prescription Hope enrollment form and following these 6 simple steps:
- Submit Information: Fill out our simple online enrollment form.
- Advocate Contact: After we receive your form, a patient advocate will contact you within 1-2 business days.
- Document Collection: Following a quick prequalification, our team will collect all necessary documents.
- Provider Coordination: All applications require healthcare provider signatures. Our team will collect all needed signatures.
- Program Submission: We put everything in order and submit your application packet to the manufacturer. We coordinate with the manufacturer throughout the processing stage.
- Medication Delivery: Following approval, qualified individuals can typically expect to receive their medication within 2 weeks. All medication ships directly from the manufacturer to the patient’s door or doctor’s office.
Prescription Hope is not a pharmacy or manufacturer. All medication is handled by the manufacturer.
Medication Delivery and Ongoing Support
After initial delivery, Prescription Hope continues to manage administrative tasks that come with patient assistance program admittance. We handle refill schedules, document updates, yearly renewals, and more.
Understanding Caplyta
How Caplyta Works
Caplyta works by affecting chemical messengers in the brain involved in mood, thinking, and behavior.
The medication helps regulate:
- Dopamine activity
- Serotonin signaling
- Glutamate-related pathways
These actions may help improve symptoms such as:
- Hallucinations
- Delusions
- Mood instability
- Depression
- Mood-related symptoms
Caplyta has a distinct receptor activity profile compared with some other atypical antipsychotic medications.
The medication is administered orally as capsules and is typically taken once daily with food under the supervision of a healthcare provider.
What Conditions Does Caplyta Treat?
Caplyta is FDA-approved for:
- Schizophrenia in adults
- Depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression) in adults:
- As monotherapy
- In combination with lithium or valproate
Schizophrenia is a chronic mental health condition that may involve hallucinations, delusions, disorganized thinking, and difficulty functioning in daily life.
Bipolar depression involves depressive episodes associated with bipolar disorder and may include symptoms such as:
- Persistent sadness
- Fatigue
- Loss of interest
- Changes in sleep or appetite
- Difficulty concentrating
Healthcare providers evaluate symptom severity, psychiatric history, treatment response, and overall health when determining whether Caplyta may be an appropriate treatment option.
Benefits of Treatment
For some patients living with schizophrenia or bipolar depression, Caplyta may provide important symptom-management benefits.
Potential benefits of Caplyta treatment may include:
- Reduction of schizophrenia symptoms
- Improvement in bipolar depression symptoms
- Once-daily oral dosing
- Relatively low rates of certain movement-related side effects in some studies
- Relatively modest effects on weight and metabolic measures in some patients during clinical studies
Response to treatment varies between individuals depending on diagnosis, symptom severity, treatment adherence, and overall mental health needs.
Because psychiatric conditions often require long-term management, ongoing follow-up care and monitoring remain important throughout treatment.
Important Safety Information and Side Effects
Caplyta carries important FDA boxed warnings and safety precautions. Patients should discuss the risks and benefits of treatment carefully with their healthcare provider before beginning therapy.
One boxed warning involves an increased risk of death in elderly patients with dementia-related psychosis treated with antipsychotic medications. Caplyta is not approved for the treatment of patients with dementia-related psychosis.
Another boxed warning involves increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults taking antidepressant-related medications.
Common side effects associated with Caplyta may include:
- Sleepiness or drowsiness
- Dry mouth
- Dizziness
- Fatigue
- Nausea
Some patients may also experience changes in appetite or weight.
Additional important safety concerns may include:
- Tardive dyskinesia (involuntary movements)
- Neuroleptic malignant syndrome
- Metabolic changes involving blood sugar and cholesterol
- Low blood pressure and fainting
- Seizures
- Leukopenia, neutropenia, and agranulocytosis
- Difficulty regulating body temperature
- Increased fall risk due to dizziness or sleepiness
- Difficulty swallowing and aspiration risk
Patients should promptly report:
- Worsening depression
- Suicidal thoughts
- Unusual movements
- Severe muscle stiffness
- Fever
- Confusion
Sleepiness and impaired alertness may affect the ability to drive or operate machinery. Patients should avoid alcohol and use caution until they understand how the medication affects them.
Drug interactions may occur with CYP3A4 inhibitors or inducers.
Monitoring during treatment may include assessments of:
- Blood sugar
- Cholesterol
- Triglycerides
- Weight
- Mood changes
- Movement-related symptoms
Patients should not stop treatment abruptly unless directed by their healthcare provider.
Access to Multiple Medications
Those who need psychiatric medication support or specialty medication assistance may need access to multiple medications at affordable rates.
Prescription Hope has access to a list of hundreds of brand-name medications. Therefore, for every medication a patient qualifies for, Prescription Hope can help.
Our service rate is $70.00 per month, per medication, no matter how many meds you qualify for.
Why Choose Prescription Hope for Caplyta Assistance
Experienced Advocacy Support
For 20 years, Prescription Hope has offered expert medication access services and advocacy support.
Ongoing Medication Management
Our team manages the administrative tasks required with patient assistance program participation, so you don’t have to.
Transparent Monthly Pricing
We charge a low service fee of $70.00 per month, per medication. And if we can’t help, you don’t pay.
Nationwide Medication Access Support
Our network has included hundreds of pharmaceutical manufacturers and tens of thousands of healthcare providers.
Those looking for bipolar depression medication support or schizophrenia treatment assistance can start by enrolling in Prescription Hope to see if they qualify for the Caplyta Patient Assistance Program. Enroll today and find out how we can help you save!
